Teva's Pivot to Growth Strategy Drives 33% Revenue Surge in Key Brands

  • Teva's key innovative brands (AUSTEDO, AJOVY, UZEDY) grew 33% YoY, reaching $1.1 billion in Q3 2026.
  • FDA approved WELTRUZA, expanding Teva's schizophrenia treatment portfolio with peak sales potential of $1.5B–$2.0B.
  • Teva acquired BXCL-501 from BioXcel Therapeutics and deepened collaboration with Samsung Bioepis for two additional biosimilars.
  • Non-GAAP gross profit margin increased to 58.7%, the highest in a decade, excluding a $500M development milestone payment from Q4 2025.
  • Teva raised its 2026 revenue outlook for AUSTEDO, AJOVY, and UZEDY, reflecting strong performance across all three brands.

Teva's strategic shift towards innovative brands and biosimilars is paying off, with significant revenue growth and margin expansion. The company's focus on neuroscience and immunology, coupled with strategic acquisitions and partnerships, positions it to capitalize on key market trends. However, the ability to execute on its ambitious pipeline and maintain profitability in a competitive landscape remains critical.

Execution Risk
Whether Teva can sustain the momentum of its key innovative brands and successfully integrate new acquisitions.
Regulatory Approvals
The pace at which Teva's pipeline products, such as ecopipam and anti-IL-15, receive regulatory approvals.
Market Dynamics
How Teva's strategic partnerships and acquisitions will impact its competitive position in the neuroscience and immunology markets.